Community Practice Connections™: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
Community Practice Connections™: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings is organized by Physicians' Education Resource, LLC (PER).
Release Date: February 27, 2023
Expiration Date: February 27, 2024
Description:
Although highly effective treatment regimens have been developed for patients with advanced classical Hodgkin lymphoma (cHL), there remains a need to optimize frontline therapy and to provide additional options for patients with relapsed/refractory disease. Thus, there is a need for education regarding current and emerging novel therapeutic approaches for HL.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real-World Settings, which was held in December 2022. This unique and engaging multimedia activity is ideal for the community-based clinician; it focuses on the practical aspects managing patients with adult and pediatric patients with cHL, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
- Devise strategies to personalize treatment of patients with HL based on patient-related factors, risk stratification, and treatment history
- Evaluate the efficacy and safety profile for current/emerging therapies among patients with advanced HL from landmark clinical trials as well as real-world data across therapy lines
- Develop strategies for proactively recognizing, monitoring, and managing adverse events associated with the use of novel therapies in the management of patients with advanced HL
- Apply recent evidence from landmark trials in advanced HL to real-world scenarios encountered in the care of patients with this malignancy